Clinical and Molecular Hepatology

"Tenofovir alafenamide"

Editorial

Viral hepatitis

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles: Hung-Yao Lin, Tai-Chung Tseng; Clin Mol Hepatol 2022;28(2):181-182.
Published online February 21, 2022; DOI: https://doi.org/10.3350/cmh.2022.0028

Citations

Citations to this article as recorded by

Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B
Log Young Kim, Jae Young Kim, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim
Journal of Medical Virology.2025;[Epub] CrossRef
Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis
Jae-Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
Hepatology International.2025; 19(4): 959. CrossRef
Long-Term Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B: Raising the Need for Studies on Functional Cure—Editorial on “Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B”
Soon Kyu Lee
The Korean Journal of Gastroenterology.2025; 85(3): 245. CrossRef
Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta‐analysis
Jeong‐Ju Yoo, Eun Ae Jung, Sang Gyune Kim, Young Seok Kim, Min Jae Kim
Journal of the International AIDS Society.2024;[Epub] CrossRef
Tenofovir Alafenamide for Multiple Drug-Resistant Chronic Hepatitis B: A 3-Year Clinical Trial
Jonggi Choi, Young-Suk Lim, Ji-Hoon Kim, Kwan Soo Byun, Byung Chul Yoo
Clinical Gastroenterology and Hepatology.2023; 21(12): 3185. CrossRef
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis
Eui Gwon Hwang, Eun-Ae Jung, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Hepatology International.2023; 17(4): 860. CrossRef
Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
Jonggi Choi, Won-Mook Choi, Young-Suk Lim
Clinics in Liver Disease.2023; 27(4): 809. CrossRef

7,952 View
129 Download
7 Web of Science
Crossref

Original Article

Viral hepatitis

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis: Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park; Clin Mol Hepatol 2022;28(2):254-264.
Published online December 28, 2021; DOI: https://doi.org/10.3350/cmh.2021.0314

Background/Aims
Tenofovir alafenamide (TAF) has shown less favorable effect on lipids compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding these outcomes in patients with chronic hepatitis B (CHB) are scarce. Therefore, this study aimed to evaluate the effect of TAF on the lipid in patients with CHB.
Methods
A total of 237 TAF-treated CHB patients compared with TDF, inactive CHB, and non-hepatitis B virus (HBV)-infected control groups using propensity score matching (PSM).
Result
s: Following PSM, each analysis was conducted on cohorts via the matching of 70:140 (TAF:TDF), 89:89 (TAF:inactive CHB), 140:560 (TAF:non-HBV infected control), and 368:1,472 (TDF:non-HBV-infected control). A significant decrease in the total cholesterol (TC) level was noted at 48 weeks in the TDF group compared to the TAF group (176.3±32.9 vs. 156.7±27.7, P<0.001) and the non-HBV-infected control group (175.0±29.5 vs. 156.2±28.3, P<0.001). However, no significant change in TC was observed in the TAF group and inactive CHB or non-HBV-infected control groups at 48 weeks. For the subgroup analyses of TAF vs. non-HBV-infected control subjects and inactive CHB patients whose detailed lipid profile information were available, no between-group differences in TC, low-density lipoprotein (LDL)-cholesterol, highdensity lipoprotein (HDL)-cholesterol, TC/HDL ratio, and LDL/HDL ratio were observed at 48 weeks.
Conclusions
TDF seems to have a lipid-lowering effect compared to the non-HBV-infected control and TAF-treated groups. However, in real practice, TAF might not worsen the lipid profiles of subjects compared to non-HBV-infected controls and patients with inactive CHB.

Citations

Citations to this article as recorded by

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment
Grace Lai‐Hung Wong, Edward Gane, Calvin Q. Pan, Scott Fung, Mang M. Ma, Namiki Izumi, Shalimar, Seng Gee Lim, Wan‐Long Chuang, Rajiv Mehta, Young‐Suk Lim, Leland J. Yee, John F. Flaherty, Frida Abramov, Hongyuan Wang, Maria Buti
Alimentary Pharmacology & Therapeutics.2026; 63(1): 132. CrossRef
Atherosclerotic Cardiovascular Risk in Patients with Chronic Hepatitis B: Tenofovir Disoproxil Fumarate Vs. Tenofovir Alafenamide: A Korean Nationwide Study
Jiwon Yang, Jihye Lim, Ye‐jee Kim, Hwa Jung Kim, Jonggi Choi
Journal of Medical Virology.2026;[Epub] CrossRef
Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First‐Time HBV‐Related Decompensated Cirrhosis
Xinxin Rong, Guangde Yang, Yuanyuan Xu, He Chen, Xia Wang, Juanjuan Fu, Li Li, Xiucheng Pan
Journal of Viral Hepatitis.2025;[Epub] CrossRef
Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B
Log Young Kim, Jae Young Kim, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim
Journal of Medical Virology.2025;[Epub] CrossRef
Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis
Jae-Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
Hepatology International.2025; 19(4): 959. CrossRef
Virological and Biochemical Effects of Tenofovir Alafenamide in Different Patient Groups With Chronic Hepatitis B Virus Infection in Real‐World Cohort
Erdem Bektas, Aysenur Yilmaz, Cevat Ilteris Kikili, Kanan Nuriyev, Zulal Istemihan, Ibrahim Volkan Senkal, Ziya Imanov, Bilger Cavus, Asli Cifcibasi Ormeci, Filiz Akyuz, Kadir Demir, Selman Fatih Besisik, Sabahattin Kaymakoglu, Sreeja Dattachoudhury
International Journal of Hepatology.2025;[Epub] CrossRef
Impact of Tenofovir Alafenamide on Lipid Profiles in Chronic Hepatitis B Patients: Systematic Review and Meta‐Analysis
Ping‐Yu Hsu, Hui‐Chen Su, Mi‐Chia Ma, Chien‐An Chen, Sin‐Yi Yu, Yi‐Ming Hua
Journal of Medical Virology.2025;[Epub] CrossRef
Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B
Witchayaporn Praguylertluck, Apichat Kaewdech, Naichaya Chamroonkul, Teerha Piratvisuth, Pimsiri Sripongpun, Tyng-Yuan Jang
PLOS One.2025; 20(5): e0324897. CrossRef
Real World Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Liver Transplant Recipients
Erdem Bektas, Aysenur Yilmaz, Cevat Ilteris Kikili, Kanan Nuriyev, Zulal Istemihan, Ibrahim Volkan Senkal, Ziya Imanov, Bilger Cavus, Asli Cifcibasi Ormeci, Filiz Akyuz, Kadir Demir, Selman Fatih Besisik, Sabahattin Kaymakoglu
Transplant Infectious Disease.2025;[Epub] CrossRef
Metabolic effects and cardiovascular disease risks of TDF or TAF in patients with chronic hepatitis B: a systematic review and meta-analysis
Yuan-Hai Zhou, Nan Cai, Yu-Xin Chen, Yong-Lu Su, Peng Hu
Frontiers in Pharmacology.2025;[Epub] CrossRef
Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent
Hyuk Kim, Jae‐Young Kim, Hyun Bin Choi, Ji‐Soo Lee, Yoon E. Shin, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim
Journal of Medical Virology.2025;[Epub] CrossRef
Evaluation of tenofovir alafenamide– versus tenofovir disoproxil fumarate–containing regimens on renal outcomes: systematic literature review and meta-analysis
Xi Liang, Kyu Yun Park, Haeseon Lee, Haopeng Liu, Connor Willis, Tara Dhippayom, Rachel Rogers, Amy R. Weinberg, Julia Green, Aileen Chi, Nathorn Chaiyakunapruk
BMC Nephrology.2025;[Epub] CrossRef
Current Clinical Applications of Entecavir in Hepatitis B Viruses Infection
Cigdem Mermutluoglu, Halim Bayram, Tugce Simsek, Abdullah Golbol, Evrim Kuscu, Hande Cam, Yusuf Arslan, Rukkiye Bulut, Hakan Celik, Mustafa Celen
International Journal of Infectious Diseases and Therapy.2025; 10(4): 68. CrossRef
Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B
Pin‐Nan Cheng, I‐Cher Feng, Jyh‐Jou Chen, Hsing‐Tao Kuo, Pei‐Lun Lee, Ming‐Lung Yu, Yen‐Cheng Chiu, Hung‐Chih Chiu, Shih‐Chieh Chien, Pei‐Jer Chen, Chun‐Jen Liu
Alimentary Pharmacology & Therapeutics.2024; 59(2): 230. CrossRef
Real‐world safety and effectiveness of tenofovir alafenamide for 144 weeks in Japanese patients with chronic hepatitis B
Shuhei Hige, Kouji Aoki, Daisuke Nakamoto, John F. Flaherty, Irina Botros, Hajime Mizutani, Akinobu Ishizaki, Hiroki Konishi, Jason Yuan, Masahisa Jinushi, Leslie J. Ng
Journal of Viral Hepatitis.2024; 31(4): 165. CrossRef
Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis
Kexin Tong, Mingjing Chen, Danni Wang, Haifeng Dai, Jiayi Peng, Jia Zhang, Jiao Zhou, Yujiao Chang, Wenxiang Huang
European Journal of Clinical Pharmacology.2024; 80(3): 335. CrossRef
Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”
Pin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology.2024; 30(4): 1031. CrossRef
Application of Tenofovir Alafenamide Fumarate in Patients with Chronic Hepatitis B
雪刘
Advances in Clinical Medicine.2024; 14(02): 3550. CrossRef
The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis
Danqing Hu, Peng Wang, Xiaojing Wang, Xue Hu, Da Huang, Weiming Yan, Dong Xi, Meifang Han, Qin Ning, Hongwu Wang
Heliyon.2024; 10(7): e28653. CrossRef
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
Pin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology.2024; 30(2): 144. CrossRef
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply
Hyeyeon Hong, Jonggi Choi
Clinical and Molecular Hepatology.2024; 30(2): 272. CrossRef
Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients
Wenjuan Zhao, Yi Liu, Mengdi Zhang, Zixin Cui, Zhan Qu, Yiyang Li, Meijuan Wan, Wen Wang, Yunru Chen, Lei Shi, Jianzhou Li, Feng Ye
Frontiers in Medicine.2024;[Epub] CrossRef
Efficacy comparison of high-genetic barrier nucleos(t)ide analogues in treatment-naïve chronic hepatitis B patients: a network meta-analysis
Jaejun Lee, Ahlim Lee, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Hyun Yang
The Korean Journal of Internal Medicine.2024; 39(4): 577. CrossRef
Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B
Hyunjae Shin, Gyung Sun Lim, Jae Woong Yoon, Yunmi Ko, Youngsu Park, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Yuri Cho, Yun Bin Lee, Eun Ju Cho, Bo Hyun Kim, Jeong‐Hoon Lee, Su Jong Yu, Jung‐Hwan Yoon, Yoon Jun Kim
Journal of Medical Virology.2024;[Epub] CrossRef
Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B
Fei Cao, Tao Fan, Xue Jiang, Jian Wang, Yilin Liu, Li Zhu, Ye Xiong, Shaoqiu Zhang, Zhiyi Zhang, Yifan Pan, Yuanyuan Li, Chao Jiang, Juan Xia, Xiaomin Yan, Jie Li, Xingxiang Liu, Chuanwu Zhu, Rui Huang, Chao Wu
Virology Journal.2024;[Epub] CrossRef
Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta‐analysis
Jeong‐Ju Yoo, Eun Ae Jung, Sang Gyune Kim, Young Seok Kim, Min Jae Kim
Journal of the International AIDS Society.2024;[Epub] CrossRef
Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
Shenglong Lin, Wanlong Huang, Ziyuan Liao, Huaxi Ma, Wenjun Wu, Minghua Lin, Defu Huang, Haibing Gao
Scientific Reports.2024;[Epub] CrossRef
Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment
Jiezuan Yang, Haifeng Lu, Baikun Chen, Lili Jiang, Hua Zhang, Ping Ye, Linfeng Jin, Lele Zhu
Journal of Immunology Research.2023; 2023: 1. CrossRef
Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis
Lili Liu, Hong Li, Yang Zhang, Jing Zhang, Zhenhuan Cao
Heliyon.2023; 9(1): e13113. CrossRef
Tenofovir Alafenamide for Multiple Drug-Resistant Chronic Hepatitis B: A 3-Year Clinical Trial
Jonggi Choi, Young-Suk Lim, Ji-Hoon Kim, Kwan Soo Byun, Byung Chul Yoo
Clinical Gastroenterology and Hepatology.2023; 21(12): 3185. CrossRef
Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation
Sihui Zhang, Chao Wang, Bei Liu, Qing-Bin Lu, Jia Shang, Yihua Zhou, Jidong Jia, Xiaoyuan Xu, Huiying Rao, Bingfeng Han, Tianshuo Zhao, Linyi Chen, Mingzhu Xie, Jiahao Cui, Juan Du, Jing zeng, Ninghua huang, Yaqiong Liu, Lei Zhang, Hui Zhuang, Fuqiang Cui
The Lancet Regional Health - Western Pacific.2023; 35: 100738. CrossRef
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis
Eui Gwon Hwang, Eun-Ae Jung, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Hepatology International.2023; 17(4): 860. CrossRef
Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis
Hui Liu, Cheng-Long Han, Bao-Wen Tian, Zi-Niu Ding, Ya-Fei Yang, Yun-Long Ma, Chun-Cheng Yang, Guang-Xiao Meng, Jun-Shuai Xue, Dong-Xu Wang, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li
Expert Review of Gastroenterology & Hepatology.2023; 17(6): 623. CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
Beom Kyung Kim, Sang Hoon Ahn
Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma
Peng Wang, Xinhui Wang, Xiaoli Liu, Fengna Yan, Huiwen Yan, Dongdong Zhou, Lihua Yu, Xianbo Wang, Zhiyun Yang
BMC Cancer.2023;[Epub] CrossRef
Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
Jonggi Choi, Won-Mook Choi, Young-Suk Lim
Clinics in Liver Disease.2023; 27(4): 809. CrossRef
Comparisons of Insulin Resistance- and Steatosis-Based Scores in Monitoring Metabolic Associated Fatty Liver Disease Treatment Response
Junzhao Ye, Yansong Lin, Congxian Shao, Yanhong Sun, Shiting Feng, Bihui Zhong
Annals of Nutrition and Metabolism.2023; 79(5): 448. CrossRef
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Clinical and Molecular Hepatology.2023; 30(1): 49. CrossRef
Incidence of Side Effects During Tenofovir Alafenamide Monotherapy in Patients with Chronic Hepatitis B
Fada Wang, Jing Zhou, Lanqing Li, Yujing Li, Yongfang Liu, Enqiang Chen
Diseases and Research.2023; 3(1): 11. CrossRef
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
Hung-Yao Lin, Tai-Chung Tseng
Clinical and Molecular Hepatology.2022; 28(2): 181. CrossRef
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B
Meng‐Lan Wang, En‐Qiang Chen
Alimentary Pharmacology & Therapeutics.2022; 56(6): 1090. CrossRef

9,519 View
312 Download
39 Web of Science
Crossref

Review

Viral hepatitis

Unmet need in chronic hepatitis B management: Lilian Yan Liang, Grace Lai-Hung Wong; Clin Mol Hepatol 2019;25(2):172-180.
Published online February 12, 2019; DOI: https://doi.org/10.3350/cmh.2018.0106

Abstract
PDF

Despite all these exciting developments, there remain some unmet needs in the management for patients with chronic hepatitis B (CHB). As majority of CHB patients are going to use oral nucleos(t)ide analogues (NAs) for decades, Safety profile of NAs is of no doubt an important issue. The newest nucleotide analogue tenofovir alafenamide is potent in terms of viral suppression, together with favourable renal and bone safety profile. Biochemical response as reflected by alanine aminotransferase (ALT) normalization is recently found to be prognostically important. Patients who achieved ALT normalization have reduced the risk of hepatic events by 49%. Functional cure as reflected by hepatitis B surface antigen seroclearance not only implies patients may stop NA treatment, it also confers to a reduced risk of hepatocellular carcinoma and other hepatic events. Hence functional cure should be the ultimate treatment goal in CHB patients. Preemptive antiviral treatment may reduce mother-to-child transmission of hepatitis B virus, especially if birth dose of vaccination cannot be given in the first two hours after delivery. Lastly, despite the currently first-line NAs have high-genetic barrier to drug resistance mutations, there are still are many patients who were previously treated with low barrier of resistance including lamivudine, telbivudine or adefovir dipivoxil which could lead to antiviral resistance and affecting the choice of NAs.

Citations

Citations to this article as recorded by

Why and when could nucleos(t)ide analogues treatment be withdrawn?
Jimmy Che-To Lai, Piero Colombatto, Grace Lai-Hung Wong, Maurizia Rossana Brunetto
Digestive and Liver Disease.2025; 57(2): 558. CrossRef
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination
Grace Lai-Hung Wong, Henry Lik-Yuen Chan
Hepatology.2025; 82(5): 1056. CrossRef
Long-Term Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B: Raising the Need for Studies on Functional Cure—Editorial on “Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B”
Soon Kyu Lee
The Korean Journal of Gastroenterology.2025; 85(3): 245. CrossRef
Nationwide analysis of renal outcomes in chronic hepatitis B patients treated with Tenofovir Alafenamide vs. Entecavir
Hyuk Kim, Jae Young Kim, Hye-Jin Yoo, Log Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
Scientific Reports.2025;[Epub] CrossRef
Envisioning a Multidisciplinary HBV Cure Research Agenda
Karine Dubé, Ali Ahmed, Chari Cohen, Yasmin Ibrahim, George A. Yendewa, Edward R. Cachay, Su Wang, Kristen Marks, Arthur Y. Kim, Jeremy Sugarman, David L. Thomas, Chloe L. Thio, Debika Bhattacharya
Current HIV/AIDS Reports.2025;[Epub] CrossRef
Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation
Bai-Guo Xu, Xue Zhang, Fang Liu, Feng-Hui Li, Xu Zhang, Hui-Ling Xiang, Jing Liang
World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
Management of Hepatitis B in Pregnancy
Jeanette Rios, Lital Aliasi-Sinai, Natalia Schmidt, Tatyana Kushner
Current Hepatology Reports.2024; 23(2): 278. CrossRef
Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy
Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim
Alimentary Pharmacology & Therapeutics.2023; 58(1): 99. CrossRef
Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir
Gui-Cai Yuan, Ai-Zhen Chen, Wei-Xin Wang, Xu-Lan Yi, Long Tu, Fang Peng, Zhi-Hong Qiu
World Journal of Clinical Cases.2023; 11(34): 8139. CrossRef
Air pollution impede ALT normalization in chronic hepatitis B patients treated with nucleotide/nucleoside analogues
Tyng-Yuan Jang, Chi-Chang Ho, Chih-Da Wu, Chia-Yen Dai, Pau-Chung Chen
Medicine.2023; 102(43): e34276. CrossRef
Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL
Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
American Journal of Gastroenterology.2022; 117(2): 288. CrossRef
Clinical Outcomes of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels
Jong-In Chang, Dong Hyun Sinn, Hyun Cho, Seonwoo Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Digestive Diseases and Sciences.2022; 67(9): 4565. CrossRef
External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Cancers.2022; 14(3): 711. CrossRef
Long‐term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study
Young Eun Chon, Soo Young Park, Seung Up Kim, Han Pyo Hong, Jae Seung Lee, Hye Won Lee, Mi Na Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Journal of Viral Hepatitis.2022; 29(4): 289. CrossRef
Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation
Zili Hu, Huilan Zeng, Jingyu Hou, Juncheng Wang, Li Xu, Yaojun Zhang, Minshan Chen, Zhongguo Zhou
Viruses.2022; 14(4): 656. CrossRef
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
Hung-Yao Lin, Tai-Chung Tseng
Clinical and Molecular Hepatology.2022; 28(2): 181. CrossRef
Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate
Lilian Yan Liang, Terry Cheuk‐Fung Yip, Jimmy Che‐To Lai, Amy Shuk‐Man Lam, Yee‐Kit Tse, Vicki Wing‐Ki Hui, Henry Lik‐Yuen Chan, Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong
Journal of Medical Virology.2022; 94(9): 4440. CrossRef
Discovery and antiviral profile of new sulfamoylbenzamide derivatives as HBV capsid assembly modulators
Leda Ivanova Bencheva, Lorena Donnici, Luca Ferrante, Adolfo Prandi, Roberta Sinisi, Marilenia De Matteo, Pietro Randazzo, Matteo Conti, Pietro Di Lucia, Elisa Bono, Leonardo Giustini, Maria Vittoria Orsale, Alexandros Patsilinakos, Edith Monteagudo, Matt
Bioorganic & Medicinal Chemistry Letters.2022; 73: 128904. CrossRef
Development and Validation of Prognostic Nomograms for Hepatocellular Carcinoma After Hepatectomy Based on Inflammatory Markers
Zili Hu, Yu Yuan, Zhiwen Hu, Qingbo Liu, Yizhen Fu, Jingyu Hou, Xuqi Sun, Shaoqiang Li, Wenbin Duan, Minshan Chen
Journal of Hepatocellular Carcinoma.2022; Volume 9: 1403. CrossRef
Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues
Tyng-Yuan Jang, Yu-Ju Wei, Ming-Lun Yeh, Shu-Fen Liu, Cheng-Ting Hsu, Po-Yao Hsu, Ta-Wei Liu, Yi-Hung Lin, Po-Cheng Liang, Meng-Hsuan Hsieh, Yu-Min Ko, Yi-Shan Tsai, Kuan-Yu Chen, Ching-Chih Lin, Pei-Chien Tsai, Shu-Chi Wang, Ching-I. Huang, Zu-Yau Lin, S
Journal of the Formosan Medical Association.2021; 120(1): 303. CrossRef
Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression
Hankil Lee, Beom Kyung Kim, Sungin Jang, Sang Hoon Ahn
Clinical and Translational Gastroenterology.2021; 12(2): e00299. CrossRef
External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Journal of Viral Hepatitis.2021; 28(6): 951. CrossRef
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong
Clinical and Molecular Hepatology.2021; 27(2): 273. CrossRef
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef
B Cell-mediated Humoral Immunity in Chronic Hepatitis B Infection
Yang Li, Shengxia Yin, Rahma Issa, Xin Tong, Guiyang Wang, Juan Xia, Rui Huang, Guangmei Chen, Dan Weng, Chen Chen, Chao Wu, Yuxin Chen
Journal of Clinical and Translational Hepatology.2021; 000(000): 000. CrossRef
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Journal of Hepatocellular Carcinoma.2021; Volume 8: 467. CrossRef
Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim
Journal of Korean Medical Science.2021;[Epub] CrossRef
The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus–related hepatocellular carcinoma
Ji Hyun Lee, Beom Kyung Kim, Soo Young Park, Won Young Tak, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Dong Hyun Sinn, Seung Up Kim
European Journal of Internal Medicine.2021; 89: 48. CrossRef
Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B
Yoon Seok Lee, Soo Min Bang, Young-Sun Lee
Journal of Clinical Medicine.2021; 10(11): 2320. CrossRef
Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial
Do Seon Song, Won Kim, Sang Hoon Ahn, Hyung Joon Yim, Jae Young Jang, Young Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Young Kul Jung, Joo Hyun Sohn, Jin-Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung K
Clinical and Molecular Hepatology.2021; 27(2): 346. CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
Cancers.2021; 13(14): 3424. CrossRef
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
Journal of Viral Hepatitis.2021; 28(11): 1570. CrossRef
Reactivation of Resolved Hepatitis B After Daratumumab for Multiple Myeloma
Soon Kyu Lee, Pil Soo Sung, Sung-Soo Park, Chang-Ki Min, Heechul Nam, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Clinical Infectious Diseases.2021; 73(6): e1372. CrossRef
The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma
Jae Min Park, Won Hyeok Choe, Jeong Han Kim, So Young Kwon, Byung Chul Yoo
Journal of Liver Cancer.2021; 21(2): 155. CrossRef
Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Cancers.2021; 13(23): 5892. CrossRef
Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway
Sung Won Lee, Sung Min Kim, Wonhee Hur, Byung-Yoon Kang, Hae Lim Lee, Heechul Nam, Sun Hong Yoo, Pil Soo Sung, Jung Hyun Kwon, Jeong Won Jang, Seong-Jun Kim, Seung Kew Yoon, Partha Mukhopadhyay
PLOS ONE.2021; 16(12): e0261067. CrossRef
An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory‐Wide Study From 2000 to 2017
Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Becky Wing‐Yan Yuen, Yee‐Kit Tse, Hester Wing‐Sum Luk, Terry Cheuk‐Fung Yip, Vicki Wing‐Ki Hui, Lilian Yan Liang, Grace Chung‐Yan Lui, Henry Lik‐Yuen Chan
Hepatology.2020; 71(2): 444. CrossRef
Reply to: “Comment on – A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea”
Beom Kyung Kim
Journal of Hepatology.2020; 72(1): 198. CrossRef
Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy
Mi Na Kim, Ju Ho Lee, Young Eun Chon, Yeonjung Ha, Seong Gyu Hwang
European Journal of Gastroenterology & Hepatology.2020; 32(3): 433. CrossRef
Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase
Hye Won Lee, Eun Hwa Kim, Jinae Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Beom Kyung Kim
Clinical and Translational Gastroenterology.2020; 11(3): e00140. CrossRef
Preferences of Patients with Chronic Hepatitis B – A Discrete Choice Experiment on the Acceptability of Functional Cure

Fraence Hardtstock, Urbano Sbarigia, Zeki Kocaata, Thomas Wilke, Shirley V Sylvester
Patient Preference and Adherence.2020; Volume 14: 613. CrossRef
Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance
Hyun Woong Lee, Jung Il Lee, Saein Kim, Sora Kim, Hye Young Chang, Kwan Sik Lee
BMC Gastroenterology.2020;[Epub] CrossRef
An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well‐controlled viremia
Hye W. Lee, Soo Y. Park, Myeongjee Lee, Eun J. Lee, Jinae Lee, Seung U. Kim, Jun Y. Park, Do Y. Kim, Sang H. Ahn, Beom K. Kim
Liver International.2020; 40(7): 1736. CrossRef
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn
Clinical and Molecular Hepatology.2020; 26(3): 352. CrossRef
Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents
Jingying Qiu, Qingqing Zhou, Yinpeng Zhang, Mingyu Guan, Xin Li, Yueting Zou, Xuan Huang, Yali Zhao, Wang Chen, Xiaoke Gu
European Journal of Medicinal Chemistry.2020; 205: 112581. CrossRef
Editorial: tenofovir disoproxil fumarate vs entecavir in patients with chronic hepatitis B and renal impairment—still an open issue
Sung Won Lee, Seung Up Kim
Alimentary Pharmacology & Therapeutics.2020; 52(5): 889. CrossRef
A multi‐centre study of trends in hepatitis B virus‐related hepatocellular carcinoma risk over time during long‐term entecavir therapy
Seung Up Kim, Yong Eun Chon, Yeon Seok Seo, Hye Won Lee, Han Ah Lee, Mi Na Kim, In Kyung Min, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Won Young Tak, Beom Kyung Kim, Soo Young Park
Journal of Viral Hepatitis.2020; 27(12): 1352. CrossRef
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee
Clinical and Molecular Hepatology.2020; 26(4): 411. CrossRef
Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion

Sojung Han, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Dai Hoon Han, Beom Kyung Kim
Journal of Hepatocellular Carcinoma.2020; Volume 7: 403. CrossRef
Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study
Seung Up Kim, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Eun Ju Lee, Hye Jung Shin, Yu Rim Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Soon Ho Um, Won Young Tak, Young Oh Kweon, Beom Kyung Kim, Soo Young Park
Cancer Epidemiology, Biomarkers & Prevention.2020; 29(4): 832. CrossRef
Reply to: “Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction”
Beom Kyung Kim
Journal of Hepatology.2019; 71(4): 847. CrossRef